Immunotherapy with OX40L-Fc or anti-CTLA-4 enhances local tissue responses and killing of Leishmania donovani

European Journal of Immunology

Volumn 34, Issue 5, 2004, Pages 1433-1440

  Zubairi, Soombul ^a   Sanos, Stephanie L ^a   Hill, Sue ^b   Kaye, Paul M ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b Cantab Pharmaceuticals Ltd   (United Kingdom)

Author keywords

Costimulation; Immunity parasites; Immunotherapy; Infection; Leishmaniasis

Indexed keywords

ANTILEISHMANIAL AGENT; CD134 ANTIGEN; CD4 ANTIGEN; CHIMERIC PROTEIN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 10; INTERLEUKIN 12; LIGAND; MONOCLONAL ANTIBODY; OX40 LIGAND; STIBOGLUCONATE SODIUM; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; TNFSF4 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; DATA ANALYSIS; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; FIBROSIS; GRANULOMA; IMMUNOTHERAPY; LEISHMANIA DONOVANI; LYMPHOCYTE PROLIFERATION; MATURATION; MOUSE; NECROSIS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TISSUE REACTION; VISCERAL LEISHMANIASIS; ANIMAL; CELL DIFFERENTIATION; DRUG EFFECT; IMMUNE SYSTEM; IMMUNOLOGY; INFLAMMATION; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; CELL DIFFERENTIATION; GRANULOMA; IMMUNE SYSTEM; IMMUNOTHERAPY; INFLAMMATION; INTERFERON TYPE II; INTERLEUKIN-12; LEISHMANIA DONOVANI; MEMBRANE GLYCOPROTEINS; MICE; TUMOR NECROSIS FACTORS;

EID: 2942711490     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200324021     Document Type: Article

References (38)

1. Grewal, I. S. and Flavell, R. A., The role of CD40 ligand in costimulation and T cell activation. Immunol. Rev. 1996. 153: 85-106.
2. Coyle, A. J. and Gutierrez-Ramos, J. C., The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat. Immunol. 2001. 2: 203-209.
3. Weinberg, A. D., OX40: targeted immunotherapy-implications for tempering autoimmunity and enhancing vaccines. Trends Immunol. 2002. 23: 102-109.
4. Thompson, C. B. and Allison, J. P., The emerging role of CTLA-4 as an immune attenuator. Immunity 1997. 7: 445-450.
5. Chambers, C. A., Kuhns, M. S., Egan, J. G. and Allison, J. P., CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immuno.l 2001. 19: 565-594.
6. Chikuma, S., Imboden, J. B. and Bluestone, J. A., Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T ILymphocyte-associated antigen 4. J. Exp. Med. 2003. 197: 129-135.
7. + regulatory T cells. Curr. Opin. Immunol. 2001. 13: 644-649.
8. Jacobsohn, D. A., Novel therapeutics for the treatment of graft- versus-host disease. Expert Opin. Investig. Drugs 2002. 11: 1271-1280.
9. van Elsas, A., Hurwitz, A. A. and Allison, J. P., Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 1999. 190: 355-366.
10. Weinberg, A. D., Rivera, M. M., Prell, R., Morris, A., Ramstad, T., Vetto, J. T., Urba, W. J., Alvord, G., Bunce, C. and Shields, J., Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol. 2000. 164: 2160-2169.
11. Guerin, P. J., Olliaro, R, Sundar, S., Boelaert, M., Croft, S. L., Desjeux, P., Wasunna, M. K. and Bryceson, A. D., Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis. 2002. 2: 494-501.
12. Croft, S. L. and Yardley, V., Chemotherapy of leishmaniasis. Curr. Pharm. Des. 2002. 8: 319-342.
13. Sundar, S., Gupta, L. B., Makharia, M. K., Singh, M. K., Voss, A., Rosenkaimer, F., Engel, J. and Murray, H. W., Oral treatment of visceral leishmaniasis with miltefosine. Ann. Trop. Med. Parasitol. 1999. 93: 589-597.
14. Murray, H. W., Montelibano, C., Peterson, R. and Sypek, J. P., Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis. J. Infect. Dis. 2000. 182: 1497-1502.
15. Murray, H. W., Lu, C. M., Mauze, S., Freeman, S., Moraine, A. L., Kaplan, G. and Coffman, R. L., Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect. Immun. 2002. 70: 6284-6293.
16. Murray, H. W., Tissue granuloma structure-function in experimental visceral leshmaniasis. Int. J. Exp. Pathol. 2001. 82: 249-267.
17. Murphy, M. L., Cotterell, S. E., Gorak, P. M., Engwerda, C. R. and Kaye, P. M., Blockade of CTLA-4 enhances host resistance to the intracellular pathogen, Leishmania donovani. J. Immunol. 1998. 161: 4153-4160.
18. Pathak, M. K. and Yi, T., Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J. Immunol. 2001. 167: 3391-3397.
19. Murray, H. W., Lu, C. M., Brooks, E. B., Fichtl, R. E., DeVecchio, J. L. and Heinzel, F. P., Modulation of T cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis. Infect. Immun. 2003. 71: 6453-6462.
20. Engwerda, C. R., Murphy, M. L., Cotterell, S. E., Smelt, S. C. and Kaye, P. M., Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani. Eur. J. Immunol. 1998. 28: 669-680.
21. Taylor, A. P. and Murray, H. W., Intracellular antimicrobial activity in the absence of interferon-gamma: effect of interleukin-12 in experimental visceral leishmaniasis in interferon-gamma genedisrupted mice. J. Exp. Med. 1997. 185: 1231-1239.
22. Humphreys, I. R., Edwards, L., Walzl, G., Rae, A. J., Dougan, G., Hill, S. and Hussell, T., OX40 ligation on activated T cells enhances the control of Cryptococcus neoformans and reduces pulmonary eosinophilia. J. Immunol. 2003. 170: 6125-6132.
23. Smelt, S. C., Cotterell, S. E., Engwerda, C. R. and Kaye, R M., B cell-deficient mice are highly resistant to Leishmania donovani infection, but develop neutrophil-mediated tissue pathology. J. Immunol. 2000. 164: 3681-3688.
24. Gomes, N. A., Gattass, C. R., Barreto-De-Souza, V., Wilson, M. E. and DosReis, G. A., TGF-beta mediates CTLA-4 suppression of cellular immunity in murine kalaazar. J. Immunol. 2000. 164: 2001-2008.
25. + regulatory T cells control Leishmania major persistence and immunity. Nature 2002. 420: 502-507.
26. + T cells. J. Immunol. 2002. 169: 3232-3241.
27. Sullivan, T. J., Letterio, J. J., van Elsas, A., Mamura, M., van Amelsfort, J., Sharpe, S., Metzler, B., Chambers, C. A. and Allison, J. P., Lack of a role for transforming growth factor-beta in cytotoxic T lymphocyte antigen-4-mediated inhibition of T cell activation. Proc. Natl. Acad. Sci. USA 2001. 98: 2587-2592.
28. Engwerda, C. R., Ato, M., Cotterell, S. E., Mynott, T. L., Tschannerl, A., Gorak-Stolinska, P. M. and Kaye, P. M., A role for tumor necrosis factor-alpha in remodeling the splenic marginal zone during Leishmania donovani infection. Am. J. Pathol. 2002. 161: 429-437.
29. Ato, M., Stager, S., Engwerda, C. R. and Kaye, P. M., Defective CCR7-dependent migration of dendritic cells contributes to the development of chronic visceral leishmaniasis. Nat. Immunol. 2002. 3: 1185-1191
30. Saha, B., Das, G., Vohra, H., Ganguly, N. K. and Mishra, G. C., Macrophage-T cell interaction in experimental visceral leishmaniasis: failure to express costimulatory molecules on Leishmania-infected macrophages and its implication in the suppression of cell-mediated immunity. Eur. J. Immunol. 1995. 25: 2492-2498.
31. Kaye, P. M., Rogers, N. J., Curry, A. J. and Scott, J. C., Deficient expression of co-stimulatory molecules on Leishmania-infected macrophages. Eur. J. Immunol. 1994. 24: 2850-2854.
32. Alexander, C. E., Kaye, P. M. and Engwerda, C. R., CD95 is required for the early control of parasite burden in the liver of Leishmania donovani-infected mice. Eur. J. Immunol. 2001. 31: 1199-1210.
33. Rogers, P. R., Song, J., Gramaglia, I., Killeen, N. and Croft, M., OX40 promotes Bel-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 2001. 15: 445-455.
34. Morris, A., Vetto, J. T., Ramstad, T., Funatake, C. J., Choolun, E., Entwisle, C. and Weinberg, A. D., Induction of antimammary cancer immunity by engaging the OX-40 receptor in vivo. Breast Cancer Res. Treat. 2001. 67: 71-80.
35. Kjaergaard, J., Peng, L., Cohen, P. A., Drazba, J. A., Weinberg, A. D. and Shu, S., Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J. Immunol. 2001. 167: 6669-6677.
36. Petty, J. K., He, K., Corless, C. L., Vetto, J. T. and Weinberg, A. D., Survival in human colorectal cancer correlates with expression of the T cell costimulatory molecule OX-40 (CD134). Am. J. Surg. 2002. 183: 512-518.
37. Murray, H. W., Effect of continuous administration of interferongamma in experimental visceral leishmaniasis. J. Infect. Dis. 1990. 161: 992-994.
38. Engwerda, C. R., Smelt, S. C. and Kaye, P. M., An in vivo analysis of cytokine production during Leishmania donovani infection in scid mice. Exp. Parasitol. 1996. 84: 195-202.